2026-04-17T03:34:02Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1829982025-11-20T15:58:55Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Cruz González, Ignacio author Torres Saura, Francisco author Trejo Velasco, Blanca author Fernández Díaz, José Antonio author Fajardo Molina, Ricardo author Valle Fernández, Raquel del author Moreno Terribas, Gerardo author Martí Sánchez, David author López Mínguez, José Ramón author Gómez Blázquez, Iván author Sanmartín Pena, Juan Carlos author Botas, Javier author Martín Lorenzo, Pedro author Palazuelos, Jorge author Albarrán Rincon, Ramón author Mohandes, Mohsen author Rodríguez Entem, Felipe José author Martí, Gerard author Valero, Ernesto author Gutiérrez, Hipólito author Amat Santos, Ignacio J. author Nombela Franco, Luis author Salinas, Pablo author Teruel, Luis author Gómez Hospital, Joan Antoni author Arzamendi, Dabit author Torres Sanabria, Mario author Calle Pérez, Germán author Cañadas Pruaño, Dolores author Pérez de Prado, Armando author Benito González, Tomás author Arroyo Úcar, Eduardo author Estévez Loureiro, Rodrigo author Caneiro Queija, Berenice author Ibañez Criado, José L. author Ruiz Nodar, Juan M. author 2022-02-07T17:24:01Z 2022-02-07T17:24:01Z 2021-12-29 2022-02-07T17:24:01Z Background: The Watchman FLX is a device upgrade of the Watchman 2.5 that incorporates several design enhancements intended to simplify left atrial appendage occlusion (LAAO) and improve procedural outcomes. This study compares peri-procedural results of LAAO with Watchman FLX (Boston Scientific, Marlborough, Massachusetts) in centers with varying degrees of experience with the Watchman 2.5 and Watchman FLX. Methods: Prospective, multicenter, 'real-world' registry including consecutive patients undergoing LAAO with the Watchman FLX at 26 Spanish sites (FLX-SPA registry). Implanting centers were classified according to the center's prior experience with the Watchman 2.5. A further division of centers according to whether or not they had performed ≤ 10 or > 10Watchman FLX implants was prespecified at the beginning of the study. Procedural outcomes of institutions stratified according to their experience with the Watchman 2.5 and FLX devices were compared. Results: 359 patients [mean age 75.5 (SD8.1), CHA2DS2-VASc 4.4 (SD1.4), HAS-BLED 3.8(SD0.9)] were included. Global success rate was 98.6%, successful LAAO with the first selected device size was achieved in 95.5% patients and the device was implanted at first attempt in 78.6% cases. There were only 9(2.5%) major peri-procedural complications. No differences in efficacy or safety results according to the centeŕs previous experience with Watchman 2.5 and procedural volume with Watchman FLX existed. Conclusions: The Watchman FLX attains high procedural success rates with complete LAA sealing in unselected, real-world patients, along with a low incidence of peri-procedural complications, regardless of operatoŕs experience with its previous device iteration or the number of Watchman FLX devices implanted. Fibril·lació auricular Implants artificials Atrial fibrillation Artificial implants Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry